Extremely favourable risk reward trade. Stoploss at 503, just above 200 week moving average. Extremely important level for any stock. It has broken the resistance level of 500 and may soon breach 100 DMA.
First target is 540 and second target is 576.
This trade does derive comfort from the general breakout of pharma sector in India.
Stock insanely undervalued with Belviq and a great board! Biotechs tend to perform well in bear markets.
I will create a google drive for company models, so that everyone has access.
1.50 is a great price to buy more if you are already in this
GL
www.tradingsignalreviews.com
CRMD saw a massive gain yesterday.
Over the course of the day we can see that the MACD historam tightens with the stock price into a triangle - suggesting a probably trend continuation (though reversal is also possible).
A major break through this formation on substantial volume will indicate whether CRMD could potentially see a second big day, or if it will...
PMC recently revised its 2016 forecast downward - sending its share price tumbling. From there the stock has been trending more or less sideways (there its little data since the drop to form a between 22 and 23 with volume declining. This suggests a major move north or south is called for - which we got just recently. Volume has picked up slightly on that move...
As per the Elliot Wave, 5 waves correction has been completed and now I expect three upward corrective waves before the its bearish downtrend resumes in its direction.
Risk/Reward: 1:5
Target: 609-616
Stoploss: 571-580
As per Elliot Wave, 5 wave correction has been completed at 580 levels and now I expect to see 3 corrective waves before it continues on to its downtrend. Markets in all indices show similar charts, and I believe the markets are ready for a short term corrective upward move.
Risk Reward: 1:5
Target 1: 609-620
Stop Loss:570
The has been absolutely no fundamental change to this bio company that has multiple big pharma partners. Yet due to the overall biotech downturn NASDAQ:PIRS was hit pretty hard. This presents a true 10 bagger opportunity , and Im not even remotely stretching the truth. The technicals show you why right now is the PERFECT time to buy. A little due diligence will...
VRX may, at first glance, look like the bloodshed is over and is moving to recovery. Not just yet. The daily MACD and StochRSI are inching toward sell indicators (see screenshot) and despite the markets upward movements today (Mon 12/14), VRX's recovery was pretty modest as more shareholders exit as they see the fall incoming.
Bottom line: Put options are a...
Harvard Apparatus Regentive Technology is a bioscience company working on more natural heart valve replacements and other pretty cool biotech stuff. However my interest is because the way they are ramping up for another go after moving from $0.60 to $3.25 in less than a month. This is shaping up to be your typical "head and shoulders" scenario. HART's 1day MACD...
Johnson & Johnson has seen extreme price consolidation since last November. Since they are a highly diversified healthcare company, currency translations affect their bottom line quite substantially. With the recent contraction of the US Dollar, Johnson & Johnson has broken out of a prolonged trading range. If the dollar continues to contract against other foreign...
With the new pressure on Bio's upon us I wanted to take a look at a stock I have long liked and especially like at this level. With new patents and a bunch of new drugs in the pipeline it will happen quickly and suddenly. The chart shows great strength as it has held up when others have fallen and I look for a move over the next month to 4.66. All it needs is a...
